Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. has announced the acceptance of its research for presentation at the EANM ’24 Congress, showcasing the preclinical success of PPMX-T002, a radioisotope labelled antibody for solid cancer treatment. The company’s research indicates the antibody, now using the alpha emitter Actinium 225, is more effective than the previous beta emitter in treating human pancreatic cancer cells in mice.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.